|
🐜
|
European multicentre study to define disease activity criteria for systemic sclerosis.* I. Clinical and epidemiological features of 290 patients from 19 centres
26 auth.
A. D. Rossa,
G. Valentini,
S. Bombardieri,
W. Bencivelli,
A. Silman,
S. d'Angelo,
M. Cerinic,
J. J. Belch,
C. Black,
R. Bečvář,
P. Bruhlman,
Franco Cozzi,
L. Czirják,
A. Drosos,
B. Dziankowska,
...
C. Ferri,
A. Gabrielli,
R. Giacomelli,
G. Hayem,
Murat Inanc,
N. McHugh,
H. Nielsen,
R. Scorza,
E. Tirri,
F. V. D. Hoogen,
P. Vlachoyiannopoulos
|
6 |
2001 |
6
🐜
|
|
🐜
|
Enhanced interleukin‐10 production by dendritic cells upon stimulation with Toll‐like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion
9 auth.
Awt van Lieshout,
MC Vonk,
Sjh Bredie,
Lba Joosten,
M. Netea,
Plcm van Riel,
...
R. Lafyatis,
F. V. D. Hoogen,
Trdj Radstake
|
5 |
2009 |
5
🐜
|
|
🐜
|
Systemic Sclerosis susceptibility or phenotype polymorphism does not confirm association with -945 promoter CTGF A large multicenter analysis of
17 auth.
J. Coenen,
Nathalie C. Lambert,
J. L. Nelson,
J. Martín,
R. García-Portales,
A. Pros,
M. Camps,
M. González-Gay,
V. Fonollosa,
M. Vonk,
...
F. V. D. Hoogen,
J. Sánchez-Román,
C. Simeón,
R. Hesselstrand,
Ariane L. Herrick,
J. Worthington,
N. Ortego-Centeno
|
0 |
2009 |
0
🐜
|
|
🐜
|
systemic sclerosis : a report from the EULAR EULAR recommendations for the treatment of
24 auth.
O. Kowal-Bielecka,
R. Landewé,
J. Avouac,
S. Chwieśko,
I. Miniati,
L. Czirják,
P. Clements,
C. Denton,
D. Farge,
K. Fligelstone,
...
I. Földvari,
D. Furst,
-. UMüller,
Ladner,
J. Seibold,
R. M. Silver,
K. Takehara,
B. G. Toth,
A. Tyndall,
G. Valentini,
F. V. D. Hoogen,
F. Wigley,
F. Zulian,
M. Matucci-Cerinic
|
0 |
2009 |
0
🐜
|
